Remove society prostate-cancer
article thumbnail

ESMO: Merck, in flurry of studies, shows Keytruda's power and limitations

Fierce Pharma

At this year’s congress of the European Society for Medical Oncology (ESMO), Merck & Co. Across four separate studies, Merck’s PD-1 juggernaut Keytruda—in combination with other cancer meds—charted complete and partial wins in cervical cancer, early breast cancer and stomach cancer.

107
107
article thumbnail

Suffering beyond physical effects: inequalities and taboos in prostate cancer

pharmaphorum

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with André Deschamps, formerly president of Europa Uomo, the voice of men with prostate cancer in Europe. Deschamps is now involved in the Let’s Talk Prostate Cancer (LTPC) Expert Group, as well as the Belgian society, Wij Ook (part of Europa Uomo).

97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Results on Novartis prostate cancer therapy could expand its use

STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

article thumbnail

ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists

Fierce Pharma

MADRID—Attendees for the European Society for Medical Oncology Congress 2023 arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitem | ESMO attendees arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitement of an industry (..)

99
article thumbnail

STAT+: What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer

STAT

Europe’s major cancer research conference kicks off in Madrid on Friday, with headline — and potentially practice-changing — readouts from trials in lung, prostate, and other types of cancer. STAT will be reporting from the annual meeting of the European Society for Medical Oncology through Monday.

102
102
article thumbnail

American Cancer Society warns about potential impact of missed screenings during Covid

STAT

When the Covid-19 pandemic brought ordinary life to a halt in 2020, routine cancer screenings fell off many people’s list of priorities. Screenings for cervical, breast, and prostate cancer all dropped in the first year of the Covid-19 pandemic, according to a new analysis from the American Cancer Society.

100
100
article thumbnail

FDA approval for Janssen’s prostate cancer treatment

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Janssen’s Akeega (niraparib and abiraterone acetate), for the treatment of adult patients BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). acquired by GlaxoSmithKline in 2019) for exclusive rights to niraparib in prostate cancer treatment.

FDA 52